About Us

Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, Parkinson's disease, multiple sclerosis, spinal cord injury, type-2 diabetes, melanoma and breast cancers, among others.
 
By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL‑1β and IL‑18.  
 
Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today.  The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands

Our Mission

Olatec is dedicated to improving the health and physical well-being of patients around the world, through the development and commercialization of our platform of safe and effective pharmaceuticals that treat a broad spectrum of inflammatory diseases.

“Olatec’s compounds represent a new class of small molecule pharmaceuticals that are synthetic, orally active, safe, IL-1β inhibitors. The data support the potential for Olatec compounds to be effective in treating a broad spectrum of inflammatory conditions and particularly autoinflammatory diseases.” ​

Charles A. Dinarello, MD
Leading expert in Inflammation, Immunology & Cellular Biology

Lead Compound

Olatec is a leader in the clinical development of safe and effective NLRP3 inhibitors addressing a broad spectrum of inflammatory diseases.  In human studies to date, Olatec's lead compound, dapansutrile (lab code: OLT1177®), is showing clinical benefit, reduction in systemic inflammation (i.e., inflammatory biomarkers) and a clean safety profile.

Our Pipeline

In addition to dapansutrile, Olatec’s platform includes approximately 60 pharmaceutical candidates.  Protecting the Company’s assets is a strong and growing portfolio of intellectual property consisting of over 180 patents and patent applications globally.

Our Science

Dapansutrile inhibits NLRP3, the sensor molecule integral in the formation of the NLRP3 inflammasome.  Inflammasomes are multiprotein complexes involved in intracellular surveillance of danger signals that trigger an intense inflammatory response, via generation of bioactive IL-1β and IL-18 through caspase-1 activation.  By specific binding to NLRP3, dapansutrile prevents the formation of the NLRP3 inflammasome, which in turn inhibits the production of IL-1β and IL-18.

Our Team

Olatec’s experienced management and drug development team, working together over 10 years, includes international thought leaders or Key Opinion Leaders (KOL), who have previously been involved in the development of first-line treatments in the NSAID and biologic classes of therapies.  These KOLs cover a wide range of disciplines and are uniquely integrated into all aspects of Olatec’s operations.